PMID- 33737853 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 1179-2744 (Print) IS - 1179-2744 (Electronic) IS - 1179-2744 (Linking) VI - 13 DP - 2021 TI - Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort. PG - 59-69 LID - 10.2147/EB.S295610 [doi] AB - PURPOSE: Retinal layer thickness parameters measured by optical coherence tomography (OCT) are emerging biomarkers of neuroaxonal degeneration and inflammation in multiple sclerosis (MS). We aimed to evaluate the value of retinal layer thickness for prediction of disability worsening and relapse in a real-world MS cohort. PATIENTS AND METHODS: For this longitudinal observational study, we included MS patients with spectral-domain OCT scans available and >/=1 year of clinical follow-up. The value of peripapillary retinal nerve fiber layer (pRNFL), macular ganglion-cell-and-inner-plexiform-layer (GCIPL) and inner nuclear layer (INL) thickness for prediction of disability worsening and relapse during the observation period was tested by multivariate models. RESULTS: We analyzed 60 MS patients during a mean observation period of 2.9 years (SD 1.8). Lower baseline thickness of GCIPL (cut-off <77microm; HR 4.1, p=0.001) and pRNFL (cut-off /=1.0microm/year and pRNFL >1.5microm/year is associated with higher likelihood of disability worsening (HR 5.7, p=0.009 and HR 6.8, p=0.003, respectively). INL thickened in patients with relapse by a mean 0.9microm while thinning by 0.3microm in patients without relapse (p=0.04). In multivariate analyses, INL thickening was associated with an increased probability of relapse (OR 17.8, p=0.023). CONCLUSION: Cross-sectional and longitudinal measurement of GCIPL and pRNFL thinning is reliable as a biomarker of disability worsening in a real-world setting. Change of INL thickness is a promising marker of relapse, i.e. inflammatory activity. CI - (c) 2021 Schurz et al. FAU - Schurz, Natascha AU - Schurz N AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Sariaslani, Lydia AU - Sariaslani L AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Altmann, Patrick AU - Altmann P AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Leutmezer, Fritz AU - Leutmezer F AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Mitsch, Christoph AU - Mitsch C AD - Department of Ophthalmology, Medical University of Vienna, Vienna, Austria. FAU - Pemp, Berthold AU - Pemp B AUID- ORCID: 0000-0002-0569-0229 AD - Department of Ophthalmology, Medical University of Vienna, Vienna, Austria. FAU - Rommer, Paulus AU - Rommer P AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Zrzavy, Tobias AU - Zrzavy T AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Berger, Thomas AU - Berger T AUID- ORCID: 0000-0001-5626-1144 AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Bsteh, Gabriel AU - Bsteh G AUID- ORCID: 0000-0002-0825-0851 AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20210312 PL - New Zealand TA - Eye Brain JT - Eye and brain JID - 101587774 PMC - PMC7966301 OTO - NOTNLM OT - biomarker OT - multiple sclerosis OT - optical coherence tomography OT - progression OT - relapse OT - retinal thinning COIS- Natascha Schurz and Lydia Sariaslani are co-first authors for this study. Fritz Leutmezer has participated in meetings sponsored by, received speaker honoraria or travel funding from Actelion, Almirall, Biogen, Celgene, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Christoph Mitsch has received honoraria for consultancy/speaking (incl. funds for e-learning modules) from Bayer, Novartis and Takeda. Berthold Pemp has received honoraria for consulting from Novartis. Paulus Rommer has received honoraria for consultancy/speaking from AbbVie, Almirall, Alexion, Biogen, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, has received research grants from Amicus, Biogen, Merck, Roche. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Celgene, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi Aventis, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. Gabriel Bsteh has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Lilly, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche and Teva. The authors report no other conflicts of interest in this work. EDAT- 2021/03/20 06:00 MHDA- 2021/03/20 06:01 PMCR- 2021/03/12 CRDT- 2021/03/19 07:20 PHST- 2020/12/09 00:00 [received] PHST- 2021/02/17 00:00 [accepted] PHST- 2021/03/19 07:20 [entrez] PHST- 2021/03/20 06:00 [pubmed] PHST- 2021/03/20 06:01 [medline] PHST- 2021/03/12 00:00 [pmc-release] AID - 295610 [pii] AID - 10.2147/EB.S295610 [doi] PST - epublish SO - Eye Brain. 2021 Mar 12;13:59-69. doi: 10.2147/EB.S295610. eCollection 2021.